{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:19:34Z","timestamp":1790050774001,"version":"4.0.1"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1001\/jamadermatol.2018.5077","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T20:56:28Z","timestamp":1548363388000},"page":"342","source":"Crossref","is-referenced-by-count":84,"title":["Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and<i>TREX1<\/i>Mutation"],"prefix":"10.1001","volume":"155","author":[{"given":"Nick","family":"Zimmermann","sequence":"first","affiliation":[{"name":"Department of Dermatology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Schwenke","sequence":"additional","affiliation":[{"name":"Rheumatological Practice, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"L\u00fcth","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Engel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ae","family":"Lee-Kirsch","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"G\u00fcnther","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"dbr180039r1","doi-asserted-by":"publisher","first-page":"11752","DOI":"10.1038\/ncomms11752","article-title":"RPA and Rad51 constitute a cell intrinsic mechanism to protect the cytosol from self DNA.","volume":"7","author":"Wolf","year":"2016","journal-title":"Nat Commun"},{"key":"dbr180039r2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev-med-050715-104506","article-title":"The type I interferonopathies.","volume":"68","author":"Lee-Kirsch","year":"2017","journal-title":"Annu Rev Med"},{"issue":"4","key":"dbr180039r3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1086\/513443","article-title":"Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome.","volume":"80","author":"Rice","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"5","key":"dbr180039r4","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/jid.2013.496","article-title":"Deregulated type I IFN response in TREX1-associated familial chilblain lupus.","volume":"134","author":"Peschke","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"5","key":"dbr180039r5","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer.","volume":"215","author":"Li","year":"2018","journal-title":"J Exp Med"},{"issue":"12","key":"dbr180039r6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"dbr180039r7","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","article-title":"Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.","volume":"138","author":"Fr\u00e9mond","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"dbr180039r8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","article-title":"Familial chilblain lupus due to a gain-of-function mutation in STING.","volume":"76","author":"K\u00f6nig","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"dbr180039r9","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"issue":"4","key":"dbr180039r10","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1086\/507848","article-title":"Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p.","volume":"79","author":"Lee-Kirsch","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"2","key":"dbr180039r11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000222430","article-title":"Familial chilblain lupus\u2014a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1.","volume":"219","author":"G\u00fcnther","year":"2009","journal-title":"Dermatology"},{"issue":"4","key":"dbr180039r12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamadermatol.2014.3438","article-title":"Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3' repair exonuclease 1 (TREX1).","volume":"151","author":"G\u00fcnther","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"20","key":"dbr180039r13","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"dbr180039r14","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1136\/annrheumdis-2016-210565","article-title":"Response to: \u2018JAK inhibition in STING-associated interferonopathy\u2019 by Crow et al.","volume":"75","author":"T\u00fcngler","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"dbr180039r15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2133.2010.09799.x","article-title":"Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus","volume":"163","author":"Kuhn","year":"2010","journal-title":"Br J Dermatol"},{"issue":"10143","key":"dbr180039r16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"dbr180039r17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","article-title":"JAK1\/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus.","volume":"136","author":"Wenzel","year":"2016","journal-title":"J Invest Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamadermatology\/article-pdf\/155\/3\/342\/17393058\/jamadermatology_zimmermann_2019_br_180039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T16:53:58Z","timestamp":1606150438000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.5077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.5077","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}